US 12,214,203 B2
Detection and treatment of neotissue
Filiep Vanpoucke, Macquarie University (AU); Floris Heutink, Macquarie University (AU); and Berit Verbist, Macquarie University (AU)
Assigned to Cochlear Limited, Macquarie University (AU)
Appl. No. 17/636,665
Filed by Cochlear Limited, Macquarie University (AU)
PCT Filed Sep. 22, 2020, PCT No. PCT/IB2020/000768
§ 371(c)(1), (2) Date Feb. 18, 2022,
PCT Pub. No. WO2021/059016, PCT Pub. Date Apr. 1, 2021.
Claims priority of provisional application 62/904,069, filed on Sep. 23, 2019.
Prior Publication US 2022/0273951 A1, Sep. 1, 2022
Int. Cl. A61N 1/05 (2006.01); A61N 1/36 (2006.01)
CPC A61N 1/36139 (2013.01) [A61N 1/0541 (2013.01); A61N 1/3614 (2017.08)] 19 Claims
OG exemplary drawing
 
1. A system, comprising:
a stimulator assembly having one or more electrodes;
a biocompatible housing connected to the stimulator assembly;
a stimulation source disposed in the biocompatible housing and configured to deliver electrical stimulation to target tissue of a recipient via the one or more electrodes; and
one or more processors configured to:
generate a current flow path using the one or more electrodes for stimulating tissue;
measure one or more transimpedance matrices for the one or more electrodes based on the current flow path;
determine neotissue formation characteristics relating to tissue growth proximate the one or more electrodes based on the one or more transimpedance matrices;
determine a treatment modification instruction to modify stimulation parameters to account for the tissue growth; and
apply the treatment modification instruction to modify ongoing stimulation provided by the apparatus.